1. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents.
- Author
-
Neri, E., Bali, M., Ba-Ssalamah, A., Boraschi, P., Brancatelli, G., Alves, F., Grazioli, L., Helmberger, T., Lee, J., Manfredi, R., Martì-Bonmatì, L., Matos, C., Merkle, E., Op De Beeck, B., Schima, W., Skehan, S., Vilgrain, V., Zech, C., Bartolozzi, C., and Bali, M A
- Subjects
- *
LIVER , *LIVER disease diagnosis , *CONTRAST media , *DELPHI method , *CRONBACH'S alpha , *MAGNETIC resonance imaging , *ABDOMINAL radiography , *BILE ducts , *CONSENSUS (Social sciences) , *DIFFERENTIAL diagnosis , *LIVER diseases , *LIVER tumors ,RESEARCH evaluation - Abstract
Objectives: To develop a consensus and provide updated recommendations on liver MR imaging and the clinical use of liver-specific contrast agents.Methods: The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) formed a multinational European panel of experts, selected on the basis of a literature review and their leadership in the field of liver MR imaging. A modified Delphi process was adopted to draft a list of statements. Descriptive and Cronbach's statistics were used to rate levels of agreement and internal reliability of the consensus.Results: Three Delphi rounds were conducted and 76 statements composed on MR technique (n = 17), clinical application of liver-specific contrast agents in benign, focal liver lesions (n = 7), malignant liver lesions in non-cirrhotic (n = 9) and in cirrhotic patients (n = 18), diffuse and vascular liver diseases (n = 12), and bile ducts (n = 13). The overall mean score of agreement was 4.84 (SD ±0.17). Full consensus was reached in 22 % of all statements in all working groups, with no full consensus reached on diffuse and vascular diseases.Conclusions: The consensus provided updated recommendations on the methodology, and clinical indications, of MRI with liver specific contrast agents in the study of liver diseases.Key Points: • Liver-specific contrast agents are recommended in MRI of the liver. • The hepatobiliary phase improves the detection and characterization of hepatocellular lesions. • Liver-specific contrast agents can improve the detection of HCC. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF